Literature DB >> 21471639

Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in AβPPswe/PS1ΔE9 mice.

Christy M Kelley1, Sylvia E Perez, Cassia R Overk, David Wynick, Elliott J Mufson.   

Abstract

Amyloid-β (Aβ) plaques occur in close apposition to thickened or swollen cholinergic and galaninergic neurites within the neocortex and hippocampus in Alzheimer's disease (AD). Despite this observation, the effect of Aβ deposition upon cholinergic and galaninergic dystrophic neurite formation remains unclear. Therefore, the purpose of this study was to evaluate the interaction between Aβ deposition within the neocortex and hippocampus upon cholinergic and galaninergic dystrophic neurite formation. Neocortical and hippocampal tissue harvested from 3- and 12-month-old amyloid-β protein precursor (AβPP)swe/PS1ΔE9 transgenic (Tg) mice were dual-immunolabeled with antibodies against either choline acetyltransferace and Aβ (10D5) or galanin (Gal) and Aβ. Stereology was used to quantify amyloid plaques and cholinergic or galaninergic dystrophic neurites. Plaque number was assessed using the optical fractionator; plaque area was calculated with the Cavalieri estimator, and dystrophic neurite numbers and thickness were manually measured. Neither amyloid nor dystrophic neuritic profiles were seen in the brains of 3-month-old Tg mice. In contrast, quantitative analysis revealed significantly more plaques in neocortex than hippocampus, with no difference in regional plaque size in 12-month-old Tg mice. Significantly more cholinergic than galaninergic dystrophic neurites-per-plaque occurred in the neocortex and hippocampus. Additionally, cholinergic dystrophic neurites were thicker than galaninergic dystrophic neurites in both regions. These data suggest that amyloid plaque deposition has a greater impact upon cholinergic than galaninergic dystrophic neurite formation in the neocortex and hippocampus in AβPPswe/PS1ΔE9 Tg mice. These data are also compatible with the hypothesis that galanin is neuroprotective and reduces dystrophic neurite formation in the face of amyloid toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471639      PMCID: PMC3307130          DOI: 10.3233/JAD-2011-102097

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  83 in total

1.  Challenging the cholinergic hypothesis in Alzheimer disease.

Authors:  P Davies
Journal:  JAMA       Date:  1999-04-21       Impact factor: 56.272

2.  Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert.

Authors:  I Sassin; C Schultz; D R Thal; U Rüb; K Arai; E Braak; H Braak
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

3.  Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation.

Authors:  Adam D Cash; Gjumrakch Aliev; Sandra L Siedlak; Akihiko Nunomura; Hisashi Fujioka; Xiongwei Zhu; Arun K Raina; Harry V Vinters; Massimo Tabaton; Anne B Johnson; Manuel Paula-Barbosa; Jesus Avíla; Paul K Jones; Rudy J Castellani; Mark A Smith; George Perry
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology.

Authors:  K F S Bell; G J L de Kort; S Steggerda; R Shigemoto; A Ribeiro-da-Silva; A C Cuello
Journal:  Neurosci Lett       Date:  2003-12-19       Impact factor: 3.046

5.  NGF and Alzheimer's disease: unfulfilled promise and untapped potential.

Authors:  J H Kordower; E J Mufson
Journal:  Neurobiol Aging       Date:  1989 Sep-Oct       Impact factor: 4.673

Review 6.  Axonal transport and Alzheimer's disease.

Authors:  Gorazd B Stokin; Lawrence S B Goldstein
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

7.  The amyloid pathology progresses in a neurotransmitter-specific manner.

Authors:  Karen F S Bell; Adriana Ducatenzeiler; Alfredo Ribeiro-da-Silva; Karen Duff; David A Bennett; A Claudio Cuello
Journal:  Neurobiol Aging       Date:  2005-11-03       Impact factor: 4.673

8.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

Authors:  D M Bowen; C B Smith; P White; A N Davison
Journal:  Brain       Date:  1976-09       Impact factor: 13.501

9.  Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.

Authors:  M S Forman; E J Mufson; S Leurgans; D Pratico; S Joyce; S Leight; V M-Y Lee; J Q Trojanowski
Journal:  Neurology       Date:  2007-03-06       Impact factor: 9.910

10.  Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease.

Authors:  Scott E Counts; Bin He; Shaoli Che; Stephen D Ginsberg; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more
  11 in total

1.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

2.  Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.

Authors:  Oludotun O Adegoke; Fangfang Qiao; Yanying Liu; Kirsty Longley; Shelley Feng; Hongmin Wang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

4.  Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Jessica A Ash; Brian E Powers; Ramon Velazquez; Melissa J Alldred; Milos D Ikonomovic; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

5.  Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain.

Authors:  Laura J Mahady; Sylvia E Perez; Dwaine F Emerich; Lars U Wahlberg; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2016-08-30       Impact factor: 3.215

6.  Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.

Authors:  Ramon Velazquez; Jessica A Ash; Brian E Powers; Christy M Kelley; Myla Strawderman; Zoe I Luscher; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neurobiol Dis       Date:  2013-04-30       Impact factor: 5.996

7.  Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  Brain Pathol       Date:  2013-07-19       Impact factor: 6.508

8.  Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease.

Authors:  Lihua Liu; Saiping Luo; Leping Zeng; Weihong Wang; Liming Yuan; Xiaohong Jian
Journal:  Neural Regen Res       Date:  2013-08-25       Impact factor: 5.135

Review 9.  3-N-butylphthalide improves neuronal morphology after chronic cerebral ischemia.

Authors:  Wanhong Zhao; Chao Luo; Jue Wang; Jian Gong; Bin Li; Yingxia Gong; Jun Wang; Hanqin Wang
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

10.  Cholinergic neurodegeneration in an Alzheimer mouse model overexpressing amyloid-precursor protein with the Swedish-Dutch-Iowa mutations.

Authors:  Bettina Maria Foidl; Patricia Do-Dinh; Bianca Hutter-Schmid; Harald R Bliem; Christian Humpel
Journal:  Neurobiol Learn Mem       Date:  2016-09-23       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.